SEC Form 10-Q Summary
Filing entity: Aeglea BioTherapeutics, Inc. The request identifies Spyre Therapeutics, Inc., but the supplied filing is for Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE). The report covers the three months ended March 31, 2021 and was filed May 10, 2021. The interim financial statements are unaudited.
Business Context and Reporting Period
Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. Its lead candidate was pegzilarginase for Arginase 1 Deficiency. The company was also developing AGLE-177 for Homocystinuria and a preclinical Cystinuria program. It had no approved products and no product sales revenue.
- Phase 3 PEACE trial of pegzilarginase was ongoing at March 31, 2021; the company subsequently reported completion of enrollment and randomization of 32 patients in April 2021, above the 30-patient target.
- Topline PEACE data was expected in the fourth quarter of 2021.
- A Phase 1/2 trial of AGLE-177 had been initiated, but COVID-19 affected site activation and first-patient dosing timing.
Financial Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue recognized | $0 | Not clearly stated in the supplied statement | — |
| Research and development expense | $11.9 million | $14.6 million | Down 19% |
| General and administrative expense | $6.4 million | $4.5 million | Up 42% |
| Total operating expenses | $18.2 million | $19.0 million | Down 4% |
| Net loss | $18.2 million | $18.7 million | Improved by $0.5 million, or 3% |
| Basic and diluted net loss per share | $0.28 | $0.57 | Improved; share count increased |
| Cash used in operating activities | $19.5 million | $21.7 million | Improved by $2.2 million |
- Net loss per share was based on 65.6 million weighted-average shares in Q1 2021 versus 33.1 million in Q1 2020.
- Stock-based compensation was $1.8 million, compared with $1.3 million in the prior-year quarter.
- Cash, cash equivalents and restricted cash totaled $82.1 million at March 31, 2021, versus $91.9 million at December 31, 2020.
- Marketable securities were $46.4 million at March 31, 2021, versus $56.2 million at year-end 2020.
- Total cash, cash equivalents, marketable securities and restricted cash were $128.5 million at March 31, 2021.
- Working capital was $119.0 million and accumulated deficit was $294.2 million.
- The company reported no debt or credit facility. Total liabilities were $39.9 million, including $7.3 million of operating lease liabilities and $21.5 million of current deferred revenue.
- Net cash provided by investing activities was $9.3 million, primarily reflecting $34.0 million of marketable-security maturities, offset by $24.3 million of purchases.
Material Changes Versus the Prior Comparable Period
- Research and development expense decreased $2.7 million, primarily because pre-commercial pegzilarginase manufacturing and certain clinical activities were completed, partly offset by higher AGLE-177 nonclinical and personnel costs.
- General and administrative expense increased $1.9 million because of increased personnel, commercial-readiness activities, professional services and legal costs.
- Operating cash burn improved by $2.2 million year over year, although the company continued to incur substantial losses.
- Interest income declined to $22,000 from $300,000 because of lower investment yields.
- Shares issued and outstanding increased to approximately 49.0 million at March 31, 2021 from approximately 48.0 million at December 31, 2020. In addition, 16.6 million pre-funded warrants remained outstanding.
Guidance, Outlook, Risks and Unusual Items
- On March 21, 2021, Aeglea entered into an exclusive license and supply agreement with Immedica Pharma AB for pegzilarginase rights in Europe, the United Kingdom, Switzerland and specified Middle Eastern markets.
- The agreement provided for a non-refundable $21.5 million upfront payment, up to approximately $130.0 million in potential regulatory and commercial milestones, and royalties in the mid-20% range on net sales in the territory.
- No revenue had been recognized from the agreement at March 31, 2021. The $21.5 million unpaid upfront amount was recorded as license receivable and deferred revenue. The agreement's estimated transaction price was $23.3 million, allocated among the license, PEACE/BLA activities and the pediatric trial.
- Management estimated that existing cash, cash equivalents and marketable securities were sufficient to fund operations into 2023, but stated that additional financing would be needed to complete all planned research and development activities.
- The company expected continuing operating losses and had no committed external source of funding. Future financing could involve equity dilution, debt restrictions or relinquishment of product rights.
- COVID-19 caused missed dosing, temporary suspension of screening, delays in enrollment and site activation, and potential risks to clinical monitoring, regulatory review, supply chains and manufacturing.
- Key development risks included failure of the PEACE trial, safety or immunogenicity issues, regulatory disagreement over clinical endpoints, manufacturing dependence on third parties, limited patient populations, competition, reimbursement uncertainty and intellectual-property challenges.
- Future minimum commitments under the Austin headquarters and laboratory lease totaled $7.8 million through April 2028. The company stated that it had no off-balance-sheet arrangements and no material pending legal proceedings.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Verify collection of the $21.5 million Immedica upfront payment and the timing of revenue recognition under the license agreement.
- Track PEACE Phase 3 topline results, regulatory filings and any changes to the expected fourth-quarter 2021 data timeline.
- Assess quarterly operating cash burn against management's stated funding runway into 2023.
- Monitor additional equity financing, use of the $34.7 million remaining under the at-the-market program, the $400.0 million shelf capacity and potential dilution from 16.6 million pre-funded warrants.
- Evaluate the effect of COVID-19 and other operational disruptions on trial enrollment, dosing, manufacturing, regulatory review and AGLE-177 development.
- Review the Immedica agreement's milestone conditions, royalty economics, continuing clinical obligations and supply requirements.
- Consider the absence of product revenue, continuing losses and the need for regulatory approval before commercialization.